文献速递脊柱关节炎

司库奇尤单抗改善持续缓解或低疾病活动度银屑病关节炎患者的身体功能与生活质量并抑制结构损伤:FUTURE 5 研究 2 年 3 期结果

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.
PubMed 文献 · RMD Open · 2023-01-01

FUTURE 5 研究纳入 996 例活动性银屑病关节炎患者,随机接受司库奇尤单抗 300 mg、150 mg(负荷/非负荷)或安慰剂治疗。至第 104 周,48%-81% 的司库奇尤单抗治疗患者达到持续低疾病活动度,19%-36% 达到持续缓解;持续低疾病活动度/缓解与身体功能、生活质量改善及结构损伤进展抑制相关。

要点

  • 至第 104 周,48%-81% 的司库奇尤单抗治疗患者达到持续低疾病活动度,19%-36% 达到持续缓解。
  • 持续低疾病活动度/缓解者身体功能与生活质量改善在数值上大于仅一次或未达到者。
  • 无论是否达到持续低疾病活动度/缓解,高比例司库奇尤单抗治疗患者 2 年内无结构进展。

核心结论

  • 持续低疾病活动度/缓解与身体功能、生活质量改善及结构损伤进展抑制相关。

研究设计与样本

  • FUTURE 5 为随机、双盲、安慰剂对照、平行分组 3 期研究,纳入活动性银屑病关节炎患者。
  • 患者随机分组:司库奇尤单抗 300 mg(N=222)、150 mg 负荷(N=220)/非负荷(N=222)及安慰剂(N=332),共 N=996。
  • 按低疾病活动度(MDA/DAPSA LDA+REM)或缓解(极低疾病活动度/DAPSA REM)状态分为未达到、达到一次或至第 104 周持续≥3 次。

主要发现

  • 至第 104 周,48%-81% 的司库奇尤单抗治疗患者达到持续低疾病活动度,19%-36% 达到持续缓解。
  • 持续低疾病活动度/缓解者身体功能与生活质量改善在数值上大于仅一次或未达到者,但所有复合指数均达到既定最小临床重要差异。
  • 无论是否达到持续低疾病活动度/缓解,高比例司库奇尤单抗治疗患者 2 年内无结构进展。
  • 基线较低年龄、较低体重指数、第 16 周压痛关节计数减少及银屑病关节炎疼痛减轻是司库奇尤单抗治疗患者持续低疾病活动度的关键预测因素。

关键数值与推荐

  • 持续低疾病活动度定义:MDA/DAPSA LDA+REM 至第 104 周持续≥3 次。
  • 持续缓解定义:极低疾病活动度/DAPSA REM 至第 104 周持续≥3 次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the impact of sustained low disease activity (LDA)/remission (REM) on physical function, quality of life (QoL) and structural outcomes in secukinumab-treated psoriatic arthritis (PsA) patients from the FUTURE 5 study. METHODS: FUTURE 5 was a randomised, double-blind, placebo-controlled, parallel-group, phase 3 study in patients with active PsA. Patients were categorised according to LDA (Minimal Disease Activity, MDA/Disease Activity index for Psoriatic Arthritis, DAPSA LDA+REM) or REM (very LDA/DAPSA REM): not achieving LDA/REM, achieving it once or sustained LDA/REM ≥3 times up to week 104. Key outcomes were improvements in Health Assessment Questionnaire Disability Index and Short Form-36 Physical Component Summary Score, proportion of non-radiographic progressors and predictors of sustained LDA response. RESULTS: Patients were randomised (N=996) into the following treatment groups: secukinumab 300 mg (N=222), secukinumab 150 mg loading (N=220)/non-loading (N=222) and placebo (N=332). Baseline characteristics were comparable between patients with sustained DAPSA and MDA responses. By week 104, 48%-81% and 19%-36% of the secukinumab-treated patients achieved sustained LDA and REM, respectively. Numerically greater improvements in physical function and QoL were observed with sustained LDA/REM versus LDA/REM achieved once or not at all, although patients reached the established minimal clinically important difference for all composite indices. A high proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA/REM. Younger age, lower body mass index at baseline, reduced tender joint count and PsA pain at week 16 were key predictors of sustained LDA in secukinumab-treated patients. CONCLUSION: Sustained LDA/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Coates LC, Mease PJ, Gladman DD, et al. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study. RMD Open. 2023. PMID: 37094983. doi:10.1136/rmdopen-2022-002939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。